IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 6, 2016, Pages 1863-1871.e6

  Desai, Avanti ^a   Jung, Mi Yeon ^a   Olivera, Ana ^a   Gilfillan, Alasdair M ^a   Prussin, Calman ^a   Kirshenbaum, Arnold S ^a   Beaven, Michael A ^b   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

IL 6; Mast cells; mastocytosis; signal transducer and activator of transcription 3; stem cell factor; suppressor of cytokine signaling 3

Indexed keywords

INTERLEUKIN 6; STEM CELL FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3; CHYMASE; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 6 RECEPTOR; PROTEIN BINDING; STEM CELL FACTOR RECEPTOR;

ARTICLE; CELL COUNT; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETIC REPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREACTIVITY; LONG TERM EXPOSURE; MAST CELL; MASTOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN METHYLATION; DNA METHYLATION; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CELL COUNT; CELL PROLIFERATION; CHYMASES; DNA METHYLATION; HUMANS; INTERLEUKIN-6; MAST CELLS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, IGE; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN;

EID: 84953245222     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.09.059     Document Type: Article

References (69)

1. T. Hirano Interleukin 6 and its receptor: ten years later Intern Rev Immunol 16 1998 249 284
2. M. Mihara, M. Hashizume, H. Yoshida, M. Suzuki, and M. Shiina IL-6/IL-6 receptor system and its role in physiological and pathological conditions Clin Sci (Lond) 122 2012 143 159
3. K. Brockow, C. Akin, M. Huber, and D.D. Metcalfe IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis Clin Immunol 115 2005 216 223
4. A. Mayado, C. Teodosio, A.C. Garcia-Montero, A. Matito, A. Rodriguez-Caballero, J.M. Morgado, and et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression Leukemia 2015 [Epub ahead of print]
5. K. Fujii, K. Konishi, Y. Kanno, and N. Ohgou Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment J Dermatol 28 2001 248 250
6. A. Kasperska-Zajac, J. Sztylc, E. Machura, and G. Jop Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients Clin Exp Allergy 41 2011 1386 1391
7. J.B. Morjaria, K.S. Babu, P. Vijayanand, A.J. Chauhan, D.E. Davies, and S.T. Holgate Sputum IL-6 concentrations in severe asthma and its relationship with FEV1 Thorax 66 2011 537
8. + cord blood cells Blood 94 1999 496 508
9. D. Schoeler, A. Grutzkau, B.M. Henz, J. Kuchler, and S. Kruger-Krasagakis Interleukin-6 enhances whereas tumor necrosis factor α and interferons inhibit integrin expression and adhesion of human mast cells to extracellular matrix proteins J Invest Dermatol 120 2003 795 801
10. A. Misiak-Tloczek, and E. Brzezinska-Blaszczyk IL-6, but not IL-4, stimulates chemokinesis and TNF stimulates chemotaxis of tissue mast cells: involvement of both mitogen-activated protein kinases and phosphatidylinositol 3-kinase signalling pathways APMIS 117 2009 558 567
11. G. Cruse, S. Cockerill, and P. Bradding IgE alone promotes human lung mast cell survival through the autocrine production of IL-6 BMC Immunol 9 2008 2
12. + pluripotent progenitor cells Methods Mol Biol 315 2006 105 112
13. J. Lappalainen, K.A. Lindstedt, and P.T. Kovanen A protocol for generating high numbers of mature and functional human mast cells from peripheral blood Clin Exp Allergy 37 2007 1404 1414
14. S.A. Jones, P.J. Richards, J. Scheller, and S. Rose-John IL-6 transsignaling: the in vivo consequences J Interferon Cytokine Res 25 2005 241 253
15. C. Garbers, N. Janner, A. Chalaris, M.L. Moss, D.M. Floss, D. Meyer, and et al. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding J Biol Chem 286 2011 14804 14811
16. M.J. Boulanger, D.C. Chow, E.E. Brevnova, and K.C. Garcia Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex Science 300 2003 2101 2104
17. D. Guschin, N. Rogers, J. Briscoe, B. Witthuhn, D. Watling, F. Horn, and et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6 EMBO J 14 1995 1421 1429
18. S.J. Rodig, M.A. Meraz, J.M. White, P.A. Lampe, J.K. Riley, C.D. Arthur, and et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses Cell 93 1998 373 383
19. R. Starr, and D.J. Hilton SOCS: suppressors of cytokine signalling Int J Biochem Cell Biol 30 1998 1081 1085
20. T. Nakahata, K. Tsuji, R. Tanaka, K. Muraoka, N. Okumura, N. Sawai, and et al. Synergy of stem cell factor and other cytokines in mast cell development Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function. Raven Press, NY 1995 13 24
21. 2 from cord blood mononuclear cells J Immunol 157 1996 343 350
22. G.H. Caughey Mast cell proteases as protective and inflammatory mediators Adv Exp Med Biol 716 2011 212 234
23. R.L. Stevens, and R. Adachi Protease-proteoglycan complexes of mouse and human mast cells and importance of their á-tryptase-heparin complexes in inflammation and innate immunity Immunol Rev 217 2007 155 167
24. H. Ochi, W.M. Hirani, Q. Yuan, D.S. Friend, K.F. Austin, and J.A. Boyce T Helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro J Exp Med 190 1999 267 280
25. T. Kikuchi, S. Ishida, T. Kinoshita, S. Sakuma, N. Sugawara, T. Yamashita, and et al. IL-6 enhances IgE-dependent histamine release from human peripheral blood-derived cultured mast cells Cytokine 20 2002 200 209
26. T.R. Hundley, A.M. Gilfillan, C. Tkaczyk, M.V. Andrade, D.D. Metcalfe, and M.A. Beaven Kit and FcϵRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells Blood 104 2004 2410 2417
27. D. Smrz, G. Bandara, M.A. Beaven, D.D. Metcalfe, and A.M. Gilfillan Prevention of F-actin assembly switches the response to SCF from chemotaxis to degranulation in human mast cells Eur J Immunol 43 2013 1873 1882
28. J. Scheller, C. Garbers, and S. Rose-John Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities Semin Immunol 26 2014 2 12
29. A. Ludwig, C. Hundhausen, M.H. Lambert, N. Broadway, R.C. Andrews, D.M. Bickett, and et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules Comb Chem High Throughput Screen 8 2005 161 171
30. C. Hundhausen, D. Misztela, T.A. Berkhout, N. Broadway, P. Saftig, K. Reiss, and et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion Blood 102 2003 1186 1195
31. L.B. Schwartz, K. Sakai, T.R. Bradford, S. Ren, B. Zweiman, A.S. Worobec, and et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis J Clin Invest 96 1995 2702 2710
32. A.M. Gilfillan, and M.A. Beaven Regulation of mast cell responses in health and disease Crit Rev Immunol 31 2011 475 529
33. 2+ signaling with particular focus on mast cells Crit Rev Immunol 29 2009 155 186
34. J. Yang, X. Liao, M.K. Agarwal, L. Barnes, P.E. Auron, and G.R. Stark Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB Genes Dev 21 2007 1396 1408
35. J.J. Babon, L.N. Varghese, and N.A. Nicola Inhibition of IL-6 family cytokines by SOCS3 Semin Immunol 26 2014 13 19
36. Y. Li, J. Deuring, M.P. Peppelenbosch, E.J. Kuipers, C. de Haar, and C.J. van der Woude IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer Carcinogenesis 33 2012 1889 1896
37. H. Isomoto, J.L. Mott, S. Kobayashi, N.W. Werneburg, S.F. Bronk, S. Haan, and et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing Gastroenterology 132 2007 384 396
38. N. Fourouclas, J. Li, D.C. Gilby, P.J. Campbell, P.A. Beer, E.M. Boyd, and et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders Haematologica 93 2008 1635 1644
39. B. He, L. You, K. Uematsu, K. Zang, Z. Xu, A.Y. Lee, and et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer Proc Natl Acad Sci U S A 100 2003 14133 14138
40. C. Lindemann, O. Hackmann, S. Delic, N. Schmidt, G. Reifenberger, and M.J. Riemenschneider SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation Acta Neuropathol 122 2011 241 251
41. Y. Niwa, H. Kanda, Y. Shikauchi, A. Saiura, K. Matsubara, T. Kitagawa, and et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma Oncogene 24 2005 6406 6417
42. F. Pierconti, M. Martini, F. Pinto, T. Cenci, S. Capodimonti, A. Calarco, and et al. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior Prostate 71 2011 318 325
43. K.D. Sutherland, G.J. Lindeman, D.Y. Choong, S. Wittlin, L. Brentzell, W. Phillips, and et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas Oncogene 23 2004 7726 7733
44. T. Tokita, C. Maesawa, T. Kimura, K. Kotani, K. Takahashi, T. Akasaka, and et al. Methylation status of the SOCS3 gene in human malignant melanomas Int J Oncol 30 2007 689 694
45. A. Weber, U.R. Hengge, W. Bardenheuer, I. Tischoff, F. Sommerer, A. Markwarth, and et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition Oncogene 24 2005 6699 6708
46. H. Isomoto Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing Digestion 79 suppl 1 2009 2 8
47. K. Shuai, and B. Liu Regulation of JAK-STAT signalling in the immune system Nat Rev Immunol 3 2003 900 911
48. J.K. Morales, Y.T. Falanga, A. Depcrynski, J. Fernando, and J.J. Ryan Mast cell homeostasis and the JAK-STAT pathway Genes Immun 11 2010 599 608
49. A. Yoshimura, M. Suzuki, R. Sakaguchi, T. Hanada, and H. Yasukawa SOCS, inflammation, and autoimmunity Front Immunol 3 2012 20
50. D.S. Hong, L.S. Angelo, and R. Kurzrock Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 110 2007 1911 1928
51. K. Brockow, and D.D. Metcalfe Mastocytosis Chem Immunol Allergy 95 2010 110 124
52. D. Traum, P. Timothee, J. Silver, S. Rose-John, M. Ernst, and D.F. LaRosa IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling J Leukoc Biol 91 2012 427 435
53. S.T. Edwards, A.C. Cruz, S. Donnelly, P.F. Dazin, E.S. Schulman, K.D. Jones, and et al. c-Kit immunophenotyping and metalloproteinase expression profiles of mast cells in interstitial lung diseases J Pathol 206 2005 279 290
54. S.A. Jones, J. Scheller, and S. Rose-John Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling J Clin Invest 121 2011 3375 3383
55. J.C. Galicia, H. Tai, Y. Komatsu, Y. Shimada, K. Akazawa, and H. Yoshie Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced Genes Immun 5 2004 513 516
56. C. Garbers, N. Monhasery, S. Aparicio-Siegmund, J. Lokau, P. Baran, M.A. Nowell, and et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases Biochim Biophys Acta 1842 2014 1485 1494
57. J. Esparza-Gordillo, H. Schaarschmidt, L. Liang, W. Cookson, A. Bauerfeind, M.A. Lee-Kirsch, and et al. A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis J Allergy Clin Immunol 132 2013 371 377
58. Y. Okugawa, C. Miki, Y. Toiyama, H. Yasuda, T. Yokoe, S. Saigusa, and et al. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer Br J Cancer 103 2010 787 795
59. R.A. Egler, S.M. Burlingame, J.G. Nuchtern, and H.V. Russell Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma Clin Cancer Res 14 2008 7028 7034
60. N.J. Peake, K. Khawaja, A. Myers, M.A. Nowell, S.A. Jones, A.D. Rowan, and et al. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor Rheumatology (Oxford) 45 2006 1485 1489
61. + pluripotent progenitor cells Methods Mol Biol 315 2006 105 112
62. A.S. Kirshenbaum, C. Akin, Y. Wu, M. Rottem, J.P. Goff, M.A. Beaven, and et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FceRI or FcgRI Leuk Res 27 2003 677 682
63. A.S. Kirshenbaum, E. Swindle, M. Kulka, Y. Wu, and D.D. Metcalfe Effect of lipopolysaccharide (LPS) and peptidoglycan (PGN) on human mast cell numbers, cytokine production, and protease composition BMC Immunol 9 2008 45
64. H.S. Kuehn, M. Radinger, and A.M. Gilfillan Measuring mast cell mediator release Curr Protoc Immunol 2010 Chapter 7:Unit7.38
65. T.R. Hundley, A.M. Gilfillan, C. Tkaczyk, M.V. Andrade, D.D. Metcalfe, and M.A. Beaven Kit and FceRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells Blood 104 2004 2410 2417
66. C. Tkaczyk, D.D. Metcalfe, and A.M. Gilfillan Determination of protein phosphorylation in FceRI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions J Immunol Methods 268 2002 239 243
67. Y. Li, J. Deuring, M.P. Peppelenbosch, E.J. Kuipers, C. de Haar, and C.J. van der Woude IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer Carcinogenesis 33 2012 1889 1896
68. A. Ludwig, C. Hundhausen, M.H. Lambert, N. Broadway, R.C. Andrews, D.M. Bickett, and et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules Comb Chem High Throughput Screen 8 2005 161 171
69. C. Hundhausen, D. Misztela, T.A. Berkhout, N. Broadway, P. Saftig, K. Reiss, and et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion Blood 102 2003 1186 1195